2020
Opioid Overdose Prevention Education for Medical Students: Adopting Harm Reduction into Mandatory Clerkship Curricula
Oldfield BJ, Tetrault JM, Wilkins KM, Edelman EJ, Capurso NA. Opioid Overdose Prevention Education for Medical Students: Adopting Harm Reduction into Mandatory Clerkship Curricula. Substance Use & Addiction Journal 2020, 41: 29-34. PMID: 31211657, DOI: 10.1080/08897077.2019.1621241.Peer-Reviewed Original ResearchConceptsHarm reduction theoryOpioid overdosesOverdose educationOpioid overdose prevention educationHarm reductionEducational interventionLow knowledgeOverdose prevention educationOpioid overdose deathsNaloxone distribution programsPublic health crisisOpioid useMedical studentsOverdose deathsOverdose preventionOverdosesModerate improvementPrevention educationNaloxoneClerkship medical studentsHealth crisisDistribution programWeeksInterventionStudents' knowledge
2016
Caring for patients with opioid use disorder in the hospitalCaring for patients with opioid use disorder in the hospital
Donroe JH, Holt SR, Tetrault JM. Caring for patients with opioid use disorder in the hospitalCaring for patients with opioid use disorder in the hospital. Canadian Medical Association Journal 2016, 188: cmaj.160290. PMID: 27647616, PMCID: PMC5135493, DOI: 10.1503/cmaj.160290.Peer-Reviewed Original Research
2012
Brief versus extended counseling along with buprenorphine/naloxone for HIV-infected opioid dependent patients
Tetrault JM, Moore BA, Barry DT, O'Connor PG, Schottenfeld R, Fiellin DA, Fiellin LE. Brief versus extended counseling along with buprenorphine/naloxone for HIV-infected opioid dependent patients. Journal Of Substance Use And Addiction Treatment 2012, 43: 433-439. PMID: 22938914, DOI: 10.1016/j.jsat.2012.07.011.Peer-Reviewed Original ResearchMeSH KeywordsAdultBuprenorphineBuprenorphine, Naloxone Drug CombinationCounselingDelivery of Health Care, IntegratedFeasibility StudiesFemaleFollow-Up StudiesHIV InfectionsHumansMaleMiddle AgedNaloxoneNarcotic AntagonistsOpioid-Related DisordersPsychotherapy, BriefSubstance Abuse DetectionTime FactorsTreatment OutcomeViral LoadConceptsEnhanced medical managementPhysician managementDetectable HIV viral loadHIV treatment settingsOpioid-negative urinesBuprenorphine/naloxoneHIV viral loadOpioid-dependent patientsPercentage of subjectsUntreated opioid dependenceExtended counselingHIV clinicHIV outcomesBuprenorphine/Medical managementOpioid dependenceViral loadDependent patientsExtensive counselingClinical trialsContinuous abstinenceNegative urineTreatment settingsGroup differencesCounseling
2006
A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care
Sullivan LE, Barry D, Moore BA, Chawarski MC, Tetrault JM, Pantalon MV, O'Connor PG, Schottenfeld RS, Fiellin DA. A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care. Clinical Infectious Diseases 2006, 43: s184-s190. PMID: 17109305, DOI: 10.1086/508182.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, SublingualAdultAntiretroviral Therapy, Highly ActiveBuprenorphineDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHIV InfectionsHumansMaleMiddle AgedNaloxoneNarcotic AntagonistsOpioid-Related DisordersPilot ProjectsProbabilityReference ValuesRisk FactorsTreatment OutcomeConceptsHIV clinical careHIV-1 RNA copies/mLBuprenorphine/naloxone treatmentRNA copies/mLCopies/mLOpioid dependenceClinical careOpioid useNaloxone treatmentPhysician managementTreatment retentionHIV type 1 RNA levelsHIV-1 RNA levelsDose of buprenorphinePartial opioid agonistRNA levelsCD4 lymphocyte countBuprenorphine/naloxoneOpioid-dependent patientsUrine toxicology testsWeeks of treatmentHuman immunodeficiency virusUrine test resultsBetter treatment retentionUntreated opioid dependence